Cancer is a severe health problem that continues to be a leading cause of death worldwide.
Increasing knowledge of the molecular mechanisms underlying cancer progression has led …

The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …

Background In a phase 2 study, rucaparib, an inhibitor of poly (ADP-ribose) polymerase
(PARP), showed a high level of activity in patients who had metastatic, castration-resistant …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …

Metastatic Prostate Cancer Interventions added to androgen-deprivation therapy in men with
metastatic prostate cancer have recently been noted to increase survival. Decisions about …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Management of metastatic prostate cancer has undergone a revolution over the past decade
with the introduction of several novel agents and repurposing of others. Several clinical trials …

Prostate cancer affects one in every nine men in the USA and is the second leading cause of
cancer-related death. The treatment landscape of advanced prostate cancer is changing …

PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced
neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically …